Please login to the form below
Turning Point Therapeutics
This page shows the latest Turning Point Therapeutics news and features for those working in and with pharma, biotech and healthcare.
Bristol Myers Squibb's lung cancer drug Augtyro receives FDA approval
The drug was added to BMS’ portfolio last year through its $4.1bn acquisition of Turning Point. ... oncology portfolio last year through its $4.1bn acquisition of Turning Point Therapeutics.
Latest news
-
Bristol Myers Squibb successfully completes acquisition of Turning Point Therapeutics
Bristol Myers Squibb (BMS) has successfully completed its acquisition of Turning Point Therapeutics (Turning Point), further expanding its oncology portfolio, the company announced. ... The company also outlined its plans to continue to explore the
More from news
Approximately 1 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Roche to acquire Carmot Therapeutics in deal worth up to $3.1bn
- Eli Lilly’s Jaypirca granted FDA accelerated approval for non-Hodgkin lymphomas
- UK-India research project trialling easy-to-use UTI test to support fight against AMR
- Cancer Research UK and Guardant collaborate to advance cancer detection and treatment
- Give the gift of positive change
- Apple Vision Pro: challenges and opportunities for pharma
No results were found
PMHub
Grace Communications
We’re an independent healthcare brand communications agency with a host of awards that speak to our success. Combining razor-sharp insights...
Latest intelligence
- New Playbook Alert: Virtual Patient Engagement
- ...
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
